A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Jul 2017 Results of post-hoc analysis published in the Urology
- 05 Jan 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 14 Dec 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History